TScan Therapeutics, Inc.
TCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2,511 | $3,076 | $2,171 | $665 |
| % Growth | -18.4% | 41.7% | 226.5% | – |
| Cost of Goods Sold | $767 | $0 | $0 | $0 |
| Gross Profit | $1,744 | $3,076 | $2,171 | $665 |
| % Margin | 69.5% | 100% | 100% | 100% |
| R&D Expenses | $31,098 | $32,634 | $29,788 | $29,354 |
| G&A Expenses | $0 | $8,919 | $8,457 | $7,295 |
| SG&A Expenses | $7,698 | $8,919 | $8,457 | $7,295 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $176 | $176 | $728 |
| Operating Expenses | $38,796 | $41,729 | $38,421 | $37,377 |
| Operating Income | -$37,052 | -$38,653 | -$36,250 | -$36,712 |
| % Margin | -1,475.6% | -1,256.6% | -1,669.7% | -5,520.6% |
| Other Income/Exp. Net | $1,342 | $1,701 | $2,123 | $903 |
| Pre-Tax Income | -$35,710 | -$36,952 | -$34,127 | -$35,809 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$35,710 | -$36,952 | -$34,127 | -$35,809 |
| % Margin | -1,422.1% | -1,201.3% | -1,571.9% | -5,384.8% |
| EPS | -0.28 | -0.28 | -0.26 | -0.3 |
| % Growth | 0% | -7.7% | 13.3% | – |
| EPS Diluted | -0.28 | -0.28 | -0.26 | -0.3 |
| Weighted Avg Shares Out | 129,836 | 129,730 | 129,679 | 120,790 |
| Weighted Avg Shares Out Dil | 129,836 | 129,730 | 129,679 | 120,790 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2,390 | $2,802 | $2,777 |
| Interest Expense | $699 | $689 | $679 | $784 |
| Depreciation & Amortization | $767 | $698 | $678 | $711 |
| EBITDA | -$34,244 | -$35,565 | -$32,770 | -$34,314 |
| % Margin | -1,363.8% | -1,156.2% | -1,509.4% | -5,160% |